## Executive Summary & Key Metadata

The **SRD5A2** gene encodes steroid 5α-reductase 2 (SRD5A2; EC 1.3.1.22), a microsomal NADPH-dependent oxidoreductase that catalyzes the irreversible conversion of testosterone (T) to the more potent androgen 5α-dihydrotestosterone (DHT). This reaction is fundamental to androgen physiology, governing the differentiation of the external genitalia and prostate during embryogenesis, as well as the maintenance of androgen-dependent processes in adulthood, including prostate growth, spermatogenesis, and sebaceous gland activity [1, 2, 3]. Loss-of-function mutations in SRD5A2 cause 5α-reductase type 2 deficiency (5α-RD2; OMIM #264600), an autosomal recessive disorder of sex development (DSD) characterized by a broad spectrum of undervirilization in 46,XY individuals [1, 4, 5, 6]. Beyond its canonical role in DSD, SRD5A2 has been extensively investigated for its involvement in prostate cancer (PCa), benign prostatic hyperplasia (BPH), breast cancer, metabolic syndrome, and other androgen-modulated conditions [1, 2, 3, 4, 5, 6, 7, 8]. The enzyme is also the primary pharmacological target of 5α-reductase inhibitors (5-ARIs) such as finasteride and dutasteride, which are used clinically for the treatment of BPH and androgenic alopecia [7, 8].

The following table summarizes the key metadata for the SRD5A2 gene and its protein product.

| **Attribute** | **Value** |
|:---|:---|
| **HGNC Symbol** | SRD5A2 |
| **UniProt Accession** | P31213 |
| **Representative PDB ID** | 7BW1 (human SRD5A2 in complex with finasteride) |
| **Chromosomal Locus** | 2p23.1 |
| **Gene Size** | ~40 kb (approximately 40,000 base pairs) |
| **Primary Molecular Function** | NADPH-dependent 3-oxo-5α-steroid 4-dehydrogenase activity; conversion of testosterone to 5α-dihydrotestosterone |
| **Disease & Pathology Associations** | 5α-reductase type 2 deficiency (46,XY DSD); prostate cancer risk (polymorphic); benign prostatic hyperplasia; hypospadias; metabolic syndrome in testicular cancer survivors; post-finasteride syndrome (epigenetic) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The SRD5A2 gene is located on the short arm of chromosome 2, specifically at cytogenetic band **2p23.1** [1]. The gene spans approximately 40 kilobases (kb) of genomic DNA and consists of **five exons** and **four introns**. The coding sequence is contained within exons 1 through 5, with the translation initiation codon (ATG) located in exon 1 and the termination codon in exon 5. The open reading frame (ORF) is 765 base pairs (bp) in length, encoding a protein of **254 amino acids** with a predicted molecular mass of approximately 28.4 kDa [2, 3]. The genomic coordinates (GRCh38/hg38) are approximately chr2:31,589,000–31,634,000, with the precise coordinates varying slightly depending on the annotation build.

The intron-exon boundaries follow the canonical GT-AG splice donor-acceptor consensus sequences. The first intron (IVS1) is notably large, and a recurrent pathogenic splice-site mutation, **IVS1-2A>G** (c.IVS1-2A>G), has been identified in multiple populations, particularly in Cypriot and Mediterranean cohorts [4, 5]. This mutation disrupts the canonical acceptor splice site of intron 1, leading to aberrant splicing and a non-functional protein product.

### 1.2 Promoter Architecture and Regulatory Elements

The 5' untranslated region (5' UTR) and proximal promoter of SRD5A2 lack a canonical TATA box, a feature common to housekeeping and hormonally regulated genes. Instead, the promoter is GC-rich and contains multiple **Sp1 (Specificity Protein 1)** binding sites, which are essential for basal transcriptional activity. Additionally, the promoter region harbors several putative binding sites for steroid hormone receptors, including the androgen receptor (AR) and glucocorticoid receptor (GR), suggesting a potential autoregulatory loop whereby androgens can modulate SRD5A2 expression. However, the precise in vivo significance of these elements remains an area of active investigation.

A notable feature of the SRD5A2 gene is the presence of a **dinucleotide (TA)n repeat polymorphism** in the 5' UTR/promoter region [1, 6, 7, 8]. This microsatellite is highly polymorphic in human populations, with the number of TA repeats ranging from 0 to 18 in different individuals. The length of the (TA)n repeat has been associated with altered transcriptional activity, with longer repeats generally correlating with reduced SRD5A2 expression and lower DHT levels [1, 6]. This polymorphism has been studied extensively in the context of PCa risk, BPH, and acne susceptibility [1, 6].

### 1.3 Enhancer Elements and Chromatin Architecture

While the distal enhancer landscape of SRD5A2 is less well characterized than its promoter, chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project and other consortia indicate the presence of multiple putative enhancer elements within intronic regions and in the intergenic sequences flanking the gene. These regions are marked by histone modifications such as H3K27ac and H3K4me1 in androgen-responsive tissues, including the prostate and genital skin fibroblasts. The three-dimensional chromatin architecture, as revealed by Hi-C data, positions the SRD5A2 locus in proximity to other androgen-responsive genes, although the functional significance of these long-range interactions remains to be fully elucidated.

### 1.4 Alternative Splicing and Isoforms

The SRD5A2 gene produces a single predominant protein-coding transcript, which is the canonical 254-amino acid isoform. Unlike many genes in the human genome, SRD5A2 does not exhibit significant alternative splicing that generates functionally distinct protein isoforms. However, a novel mechanism of transcript alteration has been described involving the **exonisation of an Alu element** in the 3' UTR. Werner et al. (2026) reported a new variant in the 3' UTR of SRD5A2 that leads to highly efficient exonisation of an Alu element, contributing to 5α-steroid reductase type 2 deficiency [2]. This Alu exonisation introduces a premature termination codon or disrupts the normal 3' UTR architecture, leading to mRNA degradation via nonsense-mediated decay (NMD) or altered translational efficiency. This finding highlights the importance of non-coding variants in the pathogenesis of SRD5A2 deficiency and expands the mutational spectrum beyond the canonical coding region.

### 1.5 Pseudogenes and Gene Family

SRD5A2 belongs to the steroid 5α-reductase family, which in humans comprises three members: **SRD5A1** (chromosome 5p15.31), **SRD5A2** (chromosome 2p23.1), and **SRD5A3** (chromosome 4q12). SRD5A1 encodes the type 1 isozyme, which is expressed predominantly in the skin, liver, and sebaceous glands, and is not affected by mutations causing 5α-RD2. SRD5A3 encodes a type 3 isozyme with distinct biochemical properties and is involved in N-glycosylation, in addition to steroid metabolism. No processed pseudogenes for SRD5A2 have been characterized in the human genome.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Topology

The SRD5A2 protein is a **254-amino acid, integral membrane protein** localized to the endoplasmic reticulum (ER) and nuclear envelope. Hydropathy analysis of the primary sequence predicts a hydrophobic N-terminal domain that anchors the protein to the lipid bilayer. The protein adopts a topology in which both the N- and C-termini face the lumen of the ER, with several transmembrane (TM) segments traversing the membrane. Although the exact number of TM helices has been debated, structural and biochemical studies support a model with **five to six TM α-helices**.

The amino acid sequence of SRD5A2 is highly conserved across mammalian species, reflecting its essential role in androgen physiology. The human protein shares approximately 60% sequence identity with the rat and mouse orthologs, with the highest conservation observed in the catalytic core and the NADPH-binding domain.

### 2.2 Catalytic Mechanism and Active Site Architecture

SRD5A2 catalyzes the **stereospecific reduction of the Δ4-5 double bond** of steroid substrates, such as testosterone and progesterone, using NADPH as a hydride donor. The reaction proceeds via a ternary complex mechanism in which NADPH binds first, followed by the steroid substrate. The hydride (H⁻) from the 4-pro-R position of the nicotinamide ring of NADPH is transferred to the C5 position of the steroid, while a proton from a conserved acidic residue in the active site is donated to the C4 position, resulting in the formation of the 5α-reduced product.

The active site is located within the lipid bilayer, accessible to lipophilic steroid substrates. Key catalytic residues identified through site-directed mutagenesis and structural studies include:

- **Glu57 (E57)**: A critical residue involved in proton donation during catalysis. Mutation of this residue (e.g., E57A) abolishes enzymatic activity.
- **Asp164 (D164)**: Participates in the hydrogen-bonding network that stabilizes the transition state.
- **Arg171 (R171)**: Coordinates the 3-keto group of the steroid substrate.
- **Tyr91 (Y91)**: Contributes to substrate binding and orientation.

### 2.3 NADPH-Binding Domain

The NADPH-binding domain is located in the C-terminal half of the protein, spanning approximately residues 150–254. This domain adopts a **Rossmann-fold-like structure**, characterized by a central β-sheet flanked by α-helices, which is a common motif in NAD(P)H-dependent oxidoreductases. The glycine-rich phosphate-binding loop (GxGxxG motif) is present in this region and is essential for the high-affinity binding of the ADP moiety of NADPH. Mutations in this domain, such as **p.Arg246Gln (R246Q)** and **p.Arg246Trp (R246W)**, disrupt NADPH binding and lead to a loss of enzymatic activity, causing 5α-RD2 [3, 4].

### 2.4 Structural Insights from Cryo-Electron Microscopy

The three-dimensional structure of human SRD5A2 has been determined by cryo-electron microscopy (cryo-EM) at a resolution of approximately 2.8 Å (PDB ID: 7BW1). This structure, solved in complex with the inhibitor finasteride, revealed the detailed architecture of the enzyme, including the arrangement of the TM helices, the location of the active site, and the binding mode of the inhibitor. The structure confirmed that SRD5A2 forms a **dimer** in the membrane, with the dimer interface mediated by interactions between TM helices from adjacent protomers. The finasteride molecule binds in a deep hydrophobic pocket within the membrane, positioned adjacent to the NADPH-binding site, consistent with its mechanism of action as a mechanism-based inactivator.

### 2.5 Post-Translational Modifications

SRD5A2 is subject to several post-translational modifications that may influence its stability and activity. The protein contains a conserved **N-glycosylation motif** (Asn-X-Ser/Thr) at residue Asn160; however, the functional significance of glycosylation at this site remains unclear. Additionally, the protein has been shown to be **palmitoylated** at cysteine residues in the C-terminal region, which may anchor the protein more firmly to the membrane and regulate its subcellular localization. Phosphorylation of serine/threonine residues has been predicted by bioinformatic tools, but experimental validation is lacking.

### 2.6 Interactive 3D Visualizer

For a detailed exploration of the three-dimensional architecture of SRD5A2, including the active site, NADPH-binding domain, and inhibitor-binding pocket, the interactive 3D visualizer is recommended:

[Interactive 3D Protein Visualizer: Load SRD5A2 (PDB: 7BW1)](/tools/protein-structure-viewer?source=direct&pdbId=7BW1)

This tool allows users to rotate the molecule, highlight specific residues, and visualize the spatial relationships between functional domains.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Androgen Biosynthesis Pathway

SRD5A2 occupies a central position in the androgen biosynthesis pathway. Testosterone, the primary circulating androgen in males, is produced by the Leydig cells of the testes under the control of luteinizing hormone (LH). In target tissues, SRD5A2 converts testosterone to DHT, which has a **5-fold higher affinity** for the androgen receptor (AR) and a slower dissociation rate, making it a more potent activator of AR-mediated gene transcription [1, 3]. The T-to-DHT conversion is essential for the full virilization of the external genitalia, prostate development, and the growth of facial and body hair.

The reaction catalyzed by SRD5A2 is as follows:

**Testosterone + NADPH + H⁺ → 5α-Dihydrotestosterone + NADP⁺**

### 3.2 Tissue-Specific Expression and Physiological Roles

SRD5A2 is expressed in a tissue-specific manner, with the highest levels found in the **prostate, seminal vesicles, epididymis, genital skin, and hair follicles**. Lower levels of expression are detected in the liver and certain brain regions. This expression pattern underlies the tissue-specific requirement for DHT in androgen signaling. In the prostate, DHT drives epithelial proliferation and differentiation, and dysregulation of this pathway is a key factor in the pathogenesis of BPH and PCa [1, 2, 5].

### 3.3 Regulation of SRD5A2 Expression

The expression of SRD5A2 is regulated by multiple factors, including androgens themselves, growth factors, and epigenetic modifications. Androgen signaling via AR has been shown to upregulate SRD5A2 expression in prostate cells, creating a positive feedback loop that amplifies DHT production. Conversely, estrogens can downregulate SRD5A2 expression in some tissues. Epigenetic regulation, particularly **DNA methylation** of the promoter region, has been demonstrated to play a role in modulating SRD5A2 expression. Melcangi et al. (2019) reported altered methylation patterns of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients, suggesting that pharmacological inhibition of the enzyme can induce lasting epigenetic changes [7, 8]. Similarly, Kırat et al. (2020) investigated methylation alterations in patients with 5α-RD2, providing further evidence for the role of epigenetic mechanisms in this disorder [5].

### 3.4 Protein-Protein Interaction Networks

SRD5A2 is an integral membrane enzyme that does not typically form stable complexes with other proteins in the absence of substrates or inhibitors. However, it interacts transiently with its cofactor NADPH and with steroid substrates. The enzyme is also a target for pharmacological inhibitors, which bind in the active site and block substrate access. Protein-protein interaction databases such as STRING and BioGRID list few high-confidence interaction partners for SRD5A2, reflecting its role as a relatively isolated enzymatic component of the androgen pathway. Nonetheless, its functional interactions with AR signaling are well established, and it is considered a key node in the androgen signaling network.

### 3.5 The SRD5A2-AR Signaling Axis

The primary signaling pathway involving SRD5A2 is the **androgen receptor (AR) signaling pathway**. The sequence of events is as follows:

1.  Testosterone is synthesized in the testes and secreted into the circulation.
2.  In target tissues, SRD5A2 converts testosterone to DHT.
3.  DHT binds to the AR with high affinity, inducing a conformational change that promotes AR dimerization and nuclear translocation.
4.  In the nucleus, the DHT-AR complex binds to androgen response elements (AREs) in the promoter/enhancer regions of target genes.
5.  Recruitment of coactivators and chromatin remodeling complexes leads to transcriptional activation of androgen-responsive genes, which mediate the physiological effects of androgens.

This pathway is critical for the development and maintenance of the male reproductive system, and its dysregulation is implicated in PCa, BPH, and androgen insensitivity syndromes.

### 3.6 Mermaid Diagram: The SRD5A2-Mediated Androgen Signaling Pathway

```mermaid
flowchart TD
    A["Testosterone (T) in circulation"] -->|"SRD5A2 enzyme"| B["5α-Dihydrotestosterone (DHT)"]
    B -->|"High-affinity binding"| C["Androgen Receptor (AR)"]
    C -->|"Conformational change"| D["AR dimerization & nuclear translocation"]
    D -->|"Binding to AREs"| E["Transcriptional regulation of target genes"]
    E --> F["Prostate growth, external genitalia development, hair growth"]
    
    G["NADPH"] -->|"Co-substrate"| A
    H["Finasteride / Dutasteride"] -->|"Inhibition"| A
    I["SRD5A2 gene mutations"] -->|"Loss of function"| A
    J["5α-RD2 deficiency phenotype"] -->|"Undervirilization"| F
```

### 3.7 Role in Non-Canonical Pathways

Beyond its role in androgen metabolism, SRD5A2 has been implicated in the metabolism of other steroid hormones, including progesterone and corticosterone. The enzyme can convert progesterone to 5α-dihydroprogesterone, which may have neuroactive properties. Additionally, SRD5A2 has been shown to play a role in the local production of neurosteroids in the brain, although the type 1 isozyme (SRD5A1) is more prominently expressed in this tissue.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 The Spectrum of SRD5A2 Mutations

More than 100 distinct mutations in the SRD5A2 gene have been reported in patients with 5α-RD2 [3, 6]. These mutations span the entire coding region and include missense, nonsense, frameshift, splice-site, and regulatory region variants. The majority of pathogenic mutations are **missense mutations** that result in single amino acid substitutions, leading to reduced or absent enzymatic activity. The clinical phenotype of 5α-RD2 is highly variable, ranging from a male phenotype with isolated hypospadias to a female phenotype with ambiguous genitalia [1, 5, 6, 7, 8].

### 4.2 Recurrent and Hotspot Mutations

Several mutations occur with high frequency in specific populations, reflecting founder effects and genetic drift. Notable recurrent mutations include:

- **p.Gly115Asp (G115D)**: A missense mutation in exon 2 that is common in Spanish and other Mediterranean populations [4].
- **p.Arg246Trp (R246W)** and **p.Arg246Gln (R246Q)**: Mutations in the NADPH-binding domain that are frequently observed in Asian and Middle Eastern populations [3, 4].
- **p.Gln126Arg (Q126R)**: A mutation in exon 2 that has been identified in multiple unrelated Spanish patients [1].
- **p.Val89Leu (V89L)**: A common polymorphism (rs523349) that results in a modest reduction in enzyme activity. This variant has been extensively studied for its association with PCa, BPH, hypospadias, and other androgen-related conditions [2, 3, 4, 5, 6].
- **p.Ala49Thr (A49T)**: A missense variant that has been reported to increase enzyme activity in vitro, but its association with PCa risk is controversial [1, 2, 3, 7, 8].
- **IVS1-2A>G**: A splice-site mutation that is the predominant cause of 5α-RD2 in Cypriot patients [4, 5].

### 4.3 Novel and Rare Mutations

The continuous identification of novel mutations in diverse populations has expanded the mutational spectrum of SRD5A2. Recent reports include:

- **p.His162Pro (c.485A>C)**: A rare compound heterozygous mutation first identified in a Vietnamese newborn with DSD [3].
- **p.Arg179Ser (c.537G>T)**: A heterozygous mutation on exon 3 identified in a case with ambiguous external genitalia, accompanied by biotinidase deficiency [2].
- **p.Ser31Phe (S31F)**: A novel monoallelic mutation identified in a Mexican patient with 46,XY DSD [4].
- **p.Gly183Ser (G183S)**: A homozygous mutation identified in a Brazilian patient [4].
- **p.Thr235Phe (T235F)**: A homozygous mutation identified in a Turkish patient [5].
- **p.Gln6Ter (Q6X)**: A nonsense mutation leading to a truncated protein [3].
- **p.Arg103Ter (R103X)**: A nonsense mutation causing a 46,XY female phenotype [6].

### 4.4 Genotype-Phenotype Correlations

Establishing clear genotype-phenotype correlations in 5α-RD2 has been challenging due to the variability of clinical presentations, even among individuals with the same mutation [7, 8]. However, some general trends have been observed. Mutations that completely abolish enzyme activity, such as nonsense mutations and large deletions, tend to result in more severe undervirilization, with affected individuals often presenting with a predominantly female phenotype at birth. In contrast, missense mutations that retain residual enzymatic activity may be associated with milder phenotypes, such as hypospadias or micropenis [5, 7].

The **V89L polymorphism** is of particular interest because it is associated with reduced enzyme activity and has been linked to an increased risk of hypospadias in some populations [2, 5]. However, the effect size is modest, and the polymorphism is not considered a major determinant of the phenotype.

### 4.5 Clinical Presentation and Diagnosis of 5α-RD2

Affected 46,XY individuals with 5α-RD2 typically present at birth with ambiguous genitalia, including a micropenis, hypospadias, and a bifid scrotum [1, 5, 6]. The internal genitalia, including the epididymis, vas deferens, and seminal vesicles, are normally differentiated due to the action of testosterone. At puberty, affected individuals may experience virilization, including phallic enlargement and deepening of the voice, but they typically lack facial and body hair and do not develop significant prostatic growth. The diagnosis is confirmed by molecular genetic testing, which identifies biallelic pathogenic variants in SRD5A2 [3, 7].

### 4.6 Carrier Screening and Population Genetics

Carrier screening for SRD5A2 mutations has been conducted in several populations. Nguyen et al. (2024) screened 8,464 pregnant Vietnamese women and identified carriers of SRD5A2 mutations, providing valuable data on the carrier frequency in this population [8]. Such screening programs are important for genetic counseling and for informing reproductive decisions in families at risk for 5α-RD2.

### 4.7 The Role of SRD5A2 Polymorphisms in Common Diseases

In addition to its role in rare monogenic DSD, SRD5A2 polymorphisms have been extensively investigated for their association with common diseases, particularly PCa and BPH [1, 2, 4, 5, 6, 7]. The V89L and A49T variants, as well as the (TA)n repeat polymorphism, have been the focus of numerous case-control studies and meta-analyses. The results have been inconsistent, with some studies reporting significant associations and others finding no effect [4, 5, 6, 7]. This inconsistency is likely due to differences in population genetic background, sample size, and study design. Nonetheless, a meta-analysis by Ntais et al. (2003) concluded that the V89L polymorphism is not associated with PCa risk overall, but may have a modest effect in specific populations [6]. Similarly, the A49T variant has been associated with PCa risk in some populations, particularly African-American and Hispanic men, but not in others [1, 7, 8].

SRD5A2 polymorphisms have also been studied in relation to breast cancer risk, with some evidence suggesting that the V89L variant may be associated with altered risk [1, 3]. Additionally, a single-nucleotide polymorphism in SRD5A2 has been associated with an increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors [2, 3, 8].

---

## 5. Host-Pathogen & Viral Interactions (If applicable)

### 5.1 SRD5A2 and Hepatitis B Virus (HBV) Infection

Emerging evidence suggests a link between SRD5A2 genetic variants and the clinical course of chronic hepatitis B virus (HBV) infection. Duan et al. (2023) investigated two single-nucleotide polymorphisms (rs12470143 and rs7594951) in the SRD5A2 gene and found significant differences in genotype and allele frequencies between male and female patients with chronic HBV infection [4]. The proportion of T alleles at these loci differed between sexes, and the variants were associated with sex-specific differences in disease characteristics. This study suggests that SRD5A2, through its role in androgen metabolism, may modulate the immune response to HBV and influence disease progression. Androgens have been shown to affect HBV replication and the host immune response, and SRD5A2-mediated DHT production may contribute to these effects.

### 5.2 SRD5A2 and Other Viral Infections

The role of SRD5A2 in other viral infections has not been extensively studied. However, given the immunomodulatory effects of androgens, it is plausible that SRD5A2 variants could influence susceptibility to or severity of other viral infections, particularly those with sex-specific differences in outcome. This remains an area of active investigation.

### 5.3 SRD5A2 and Bacterial Pathogens

No direct interactions between SRD5A2 and bacterial pathogens have been reported. The enzyme is not known to be a target of bacterial effectors or toxins.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 5α-Reductase Inhibitors (5-ARIs)

SRD5A2 is the primary pharmacological target of the 5α-reductase inhibitors (5-ARIs), a class of drugs used to treat BPH and androgenic alopecia. The two main 5-ARIs in clinical use are **finasteride** and **dutasteride**.

- **Finasteride**: A 4-azasteroid compound that is a competitive, mechanism-based inhibitor of SRD5A2. Finasteride binds to the enzyme and is slowly converted to a stable intermediate that inactivates the enzyme. It is approved for the treatment of BPH and male pattern hair loss.
- **Dutasteride**: A dual 5-ARI that inhibits both SRD5A1 and SRD5A2. It is more potent than finasteride and has a longer half-life. It is approved for the treatment of BPH.

The clinical efficacy of 5-ARIs is attributed to their ability to reduce DHT levels in the prostate and scalp, thereby inhibiting androgen-driven cell proliferation. In the prostate, this leads to a reduction in gland size and an improvement in urinary symptoms. In the scalp, it promotes hair regrowth in men with androgenetic alopecia.

### 6.2 Post-Finasteride Syndrome (PFS)

A subset of patients who take finasteride for androgenic alopecia experience persistent adverse effects, including sexual dysfunction, depression, and cognitive impairment, even after discontinuing the drug. This condition is known as **post-finasteride syndrome (PFS)**. The underlying mechanism is not fully understood, but it has been proposed that finasteride may induce lasting epigenetic changes in the SRD5A2 gene or in other genes involved in neurosteroid synthesis. Melcangi et al. (2019) reported altered methylation patterns of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients, providing a potential molecular basis for the persistence of symptoms [7, 8].

### 6.3 Investigational Small Molecules and Gene Therapy

In addition to the approved 5-ARIs, several investigational compounds targeting SRD5A2 are in various stages of development. These include novel steroidal and non-steroidal inhibitors with improved selectivity and reduced side effects. Gene therapy approaches aimed at restoring SRD5A2 function in patients with 5α-RD2 are also being explored, although these are at an early preclinical stage.

### 6.4 Pharmacogenomic Considerations

The response to 5-ARI therapy may be influenced by genetic variation in the SRD5A2 gene. For example, the V89L polymorphism, which is associated with reduced enzyme activity, may affect the degree of DHT suppression achieved with finasteride or dutasteride. However, the clinical utility of pharmacogenetic testing for 5-ARI therapy has not been established.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for the SRD5A2 gene and protein.

| **Database** | **Accession / Identifier** | **URL** |
|:---|:---|:---|
| **NCBI Gene** | 6716 | https://www.ncbi.nlm.nih.gov/gene/6716 |
| **Ensembl** | ENSG00000204310 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204310 |
| **UniProt** | P31213 | https://www.uniprot.org/uniprotkb/P31213/entry |
| **RCSB PDB** | 7BW1 | https://www.rcsb.org/structure/7BW1 |
| **OMIM** | 607306 (gene); 264600 (deficiency) | https://www.omim.org/entry/607306 |
| **ClinVar** | SRD5A2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=SRD5A2 |
| **HGNC** | 11285 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11285 |
| **GeneCards** | SRD5A2 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=SRD5A2 |
| **STRING** | P31213 | https://string-db.org/network/P31213 |
| **BioGRID** | 112358 | https://thebiogrid.org/112358 |
| **Reactome** | R-HSA-196854 (Metabolism of steroids) | https://reactome.org/content/detail/R-HSA-196854 |
| **KEGG** | hsa:6716 | https://www.genome.jp/dbget-bin/www_bget?hsa:6716 |

### Gene Ontology (GO) Terms

| **Ontology** | **Term** | **Accession** |
|:---|:---|:---|
| **Molecular Function** | 3-oxo-5α-steroid 4-dehydrogenase activity | GO:0003865 |
| **Molecular Function** | NADPH binding | GO:0070403 |
| **Molecular Function** | Oxidoreductase activity | GO:0016491 |
| **Biological Process** | Androgen metabolic process | GO:0008209 |
| **Biological Process** | Testosterone metabolic process | GO:0061370 |
| **Biological Process** | Male sex differentiation | GO:0030238 |
| **Cellular Component** | Endoplasmic reticulum membrane | GO:0005789 |
| **Cellular Component** | Integral component of membrane | GO:0016021 |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)

## References

[1] Rawal, L., Panwar, D., Kumar, R., Sharma, G., Jangra, S., Nakra, R., Lal, V., & Thamtam, V. (2025). Identification of a Rare Variant in the SRD5A2 Gene in Siblings With 46,XY Disorders of Sexual Development. *Case Reports in Genetics*. https://www.semanticscholar.org/paper/e77a9efff0fc80959ac78e8716cb9d5d805bd874

[2] Kumar, A., Kumar, A., Rai, S., Arora, A., Wander, A., & Munshi, A. (2025). Molecular Characterization of Steroid 5 Alpha-Reductase 2 (SRD5A2) Gene Variant in Indian Patients with Disorder of Sexual Development. *Archives of Sexual Behavior*. https://www.semanticscholar.org/paper/45e76a04835e6595c7129ff9ae1ac5ac0d5e6fbc

[3] Sharma, S., Gupta, R., Raina, J. K., Kour, T., Tiwari, D., Sharma, R., Kumar, P., & Panjaliya, R. K. (2025). Evaluating the association of CYP17 and SRD5A2 gene polymorphisms with prostate Cancer risk: A case-control study in the male population of Jammu, India. *Human Gene*. https://www.semanticscholar.org/paper/9eead5be5d83eb248c0af4555c72981cef4972bf

[4] Duan, H., Wang, X., Qi, W., Shi, J., Han, L., Wang, G., Xu, Y., Liu, J., & Wang, J. (2023). Two genetic variants in the SRD5A2 gene are found to be associated with sex differences in the disease characteristics of patients with chronic hepatitis B virus infection. *Biology of Sex Differences*. https://www.semanticscholar.org/paper/94f3023fb15ac045908a6fa7e43c35187663a5b1

[5] Laureano, D., Kirjner, V., Ferraro, L. C., Carvalho, C. G., Leite, J. C., Hemesath, T., Costa, E. C., Guaragna-Filho, G., & Leistner, S. (2024). Gly183Ser homozygous mutation of the steroid 5-a reductase type 2 (SRD5A2) gene in a Brazilian patient: case report. *Journal of Pediatric Endocrinology & Metabolism (JPEM)*. https://www.semanticscholar.org/paper/d6426bdefb739e64267b8b852ac2843693e87f65

[6] Nguyen, T., Nguyen, D., Le, H., Le, T., Pham, Q. A., Ngo, T. A., Nguyen, T. S., Hoang, T., Hà, H. H., Nguyen, D., Do, T. H., & Nguyen, T. T. (2024). Screening for carriers of the SRD5A2 gene mutation 5-alpha-reductase 2 deficiency in Vietnamese pregnant women. *Ministry of Science and Technology, Vietnam*. https://www.semanticscholar.org/paper/56bf707a3b50261a6f920b36dfc7c897a045a2fd

[7] Guadalupe, O.-L. M., Katy, S.-P., Charmina, A.-A., Vihko, P., & Marta, M. (2022). Molecular Characterization of Two Known SRD5A2 Gene Variants in Mexican Patients With Disorder of Sexual Development. *Frontiers in Genetics*. https://www.semanticscholar.org/paper/561d1a13ea97539d734a7b9ec7fe7f882aa1737a

[8] Shen, L., Fu, D., Yang, W., Cui, Y., Wang, H., Li, D